CoChat

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; 6 of the 28 sources its claims cite were checked for support.

Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone

Open access
Sassa, Shigeru, Kappas, Attallah · 1983 · Journal of Clinical Investigation

Abstract

Succinylacetone (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumarylacetoacetate hydrolase. It is known that patients with this hereditary disease excrete excessive amounts of delta-aminolevulinic acid (ALA) in urine and that certain patients have an accompanying clinical syndrome resembling that of acute intermittent porphyria (AIP). In order to elucidate the relation of succinylacetone to the heme biosynthetic pathway, we have examined the effects of this metabolite on the cellular heme content of cultured avian hepatocytes and on the activity of purified ALA dehydratase from normal human erythrocytes and from mouse and bovine liver. Our data indicate that succinylacetone is an extremely potent competitive inhibitor of ALA dehydratase in human as well as in animal tissues. By using purified preparations of the enzyme from human erythrocytes and mouse and bovine liver, an inhibitor constant ranging from 2 x 10(-7) M to 3 x 10(-7) M was obtained. In cultured hepatocytes, succinylacetone also inhibited ALA dehydratase activity, decreased the cellular content of heme and cytochrome P-450, and greatly potentiated the induction response of ALA synthase to drugs such as phenobarbital, chemicals such as allylisopropylacetamide and 3,5-dicarbethoxy-1,4-dihydrocollidine, and natural steroids such as etiocholanolone. Four patients with hereditary tyrosinemia have been studied and all were found to have greatly depressed levels of erythrocyte ALA dehydratase activity and elevated concentrations of this inhibitor in urine. These findings indicate that tyrosinemia is a disorder of special pharmacogenetic interest because succinylacetone, an abnormal product of the tyrosine metabolic pathway, resulting from the primary gene defect of the disease, profoundly inhibits heme biosynthesis in normal cells through a blockade at the ALA dehydratase level, leading to clinical and metabolic consequences that mimic another genetic disease, AIP.

Overview

CoChat Summary

TL;DR

This paper shows that succinylacetone, a metabolite that accumulates in hereditary tyrosinemia, is a very potent competitive inhibitor of δ-aminolevulinic acid dehydratase (ALA dehydratase), linking the disorder to blocked heme biosynthesis. In cultured chick embryo liver cells it lowers heme and cytochrome P-450 and greatly sensitizes ALA synthase induction, helping explain AIP-like features in some patients.

Key findings

  • Succinylacetone competitively inhibited purified ALA dehydratase from human erythrocytes, mouse liver, and bovine liver, with inhibitor constants in the range of 2–3 × 10^-7 M and enzyme Km values of 1.5–2.2 × 10^-4 M, implying about 1,000-fold greater affinity for the enzyme than ALA.
  • In cultured chick embryo liver cells, succinylacetone caused dose-dependent inhibition of ALA dehydratase and reduced heme metabolism; at 10^-8 M it decreased cytochrome P-450 by >50%, and total heme fell from 155±8 to 112±3 pmol/mg protein.
  • Succinylacetone potentiated ALA synthase induction by porphyrogenic agents by about 3- to 16-fold; with AIA, the lowest detectable induction shifted from >0.5 μg/ml to 0.05 μg/ml (a 10-fold increase in sensitivity).
  • In the four hereditary tyrosinemia patients studied, erythrocyte ALA dehydratase activity ranged from 0.4% to 38% of control; in one case it was below the detection limit (<10 nmol PBG/ml RBC·h), and the patient’s urine inhibited normal ALA dehydratase by 28–79%.

Methods

  • The study examined four patients with hereditary tyrosinemia, purified ALA dehydratase from human erythrocytes, mouse liver, and bovine liver, and used cultured chick embryo liver cells to test heme metabolism and induction responses.
  • ALA dehydratase was purified by chromatography and fractionation methods; inhibition was assayed using purified enzyme preparations and liver-cell homogenates, and heme, cytochrome P-450, heme oxygenase, and ALA synthase were measured in cultured hepatocytes.
  • Main analyses included competitive inhibition kinetics (including Dixon plots and Km/Ki comparisons), dose-response assays in cell culture, and rocket immunoelectrophoresis to assess whether patient erythrocytes contained normal amounts of ALA dehydratase protein.

Limitations

  • The paper explicitly notes that some findings are “unpublished results” and that one patient’s post-treatment enzyme values were reported as “submitted for publication”, so not all supporting data are fully presented here.
  • The text gives only a small clinical sample: four patients with hereditary tyrosinemia, which limits generalization; this is evident from the study design.
  • The paper states that several mechanistic points remain speculative, including how succinylacetone blocks ALA binding and the precise basis of the AIP-like neurological symptoms; this is stated in the discussion as unresolved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci110809

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Analytical SDS polyacrylamide gel electrophoresis of human erythrocyte ALA dehydratase. Approximately 10 μg of enzyme was applied to the gel and the electrophoresis was carried out at pH 8.3 as described in Methods. The ALA dehydratase had a M, = 34,000. Molecular weight standards used were:(a) phosphorylase b (M, = 94,000), (b) bovine serum albumin (M, = 67,000), (c) ovalbumin (M, = 43,000), (d) carbonic anhydrase (M = 30,000), (e) soybean trypsin inhibitor (M, = 20,100), and (f) α-lactalbumin (M, = 14,400)
FIGURE 1 Analytical SDS polyacrylamide gel electrophoresis of human erythrocyte ALA dehydratase. Approximately 10 μg of enzyme was applied to the gel and the electrophoresis was carried out at pH 8.3 as described in Methods. The ALA dehydratase had a M, = 34,000. Molecular weight standards used were:(a) phosphorylase b (M, = 94,000), (b) bovine serum albumin (M, = 67,000), (c) ovalbumin (M, = 43,000), (d) carbonic anhydrase (M = 30,000), (e) soybean trypsin inhibitor (M, = 20,100), and (f) α-lactalbumin (M, = 14,400)From the PDF
FiGURE 2 Dixon plot of purified human erythrocyte ALA dehydratase activity as a function of succinylacetone concentration. Enzyme assays were carried out as described previously (9). The K for succinylacetone was determined to be 3.0 × 10-7 M at the intersection point as shown.
FiGURE 2 Dixon plot of purified human erythrocyte ALA dehydratase activity as a function of succinylacetone concentration. Enzyme assays were carried out as described previously (9). The K for succinylacetone was determined to be 3.0 × 10-7 M at the intersection point as shown.From the PDF
FiGURE 3 Effects of succinylacetone (SA) on ALA dehydratase activity in cultured chick embryo liver cells. Liver cells were prepared and incubations were carried out as described in Methods. Succinylacetone was added at the time of change of medium 24 h after incubation and cells were further incubated with succinylacetone for 24 h (O O), or the chemical was added to homogenates of liver cells obtained after 48 h incubation n culture (● - - - ●). Control enzyme activity in cultured liver cells was 3.9 nmol/mg protein·h and in homogenates was 3.7 nmol/mg protein·h. Data represent the mean of duplicate determinations.
FiGURE 3 Effects of succinylacetone (SA) on ALA dehydratase activity in cultured chick embryo liver cells. Liver cells were prepared and incubations were carried out as described in Methods. Succinylacetone was added at the time of change of medium 24 h after incubation and cells were further incubated with succinylacetone for 24 h (O O), or the chemical was added to homogenates of liver cells obtained after 48 h incubation n culture (● - - - ●). Control enzyme activity in cultured liver cells was 3.9 nmol/mg protein·h and in homogenates was 3.7 nmol/mg protein·h. Data represent the mean of duplicate determinations.From the PDF
Image 4
From the PDF
FIGURE 5 Potentiation of AIA-induction of ALA synthase by succinylacetone (SA) in cultured chick embryo liver cells. Conditions of cell cultures were the same as in Fig. 4. Addition of chemicals was made at the time of change of medium after 24 h incubation and cells were then incubated for an additional 24 h. ALA synthase assays were carried out as described previously (8). Data represent the mean±SE for triplicate determinations.
FIGURE 5 Potentiation of AIA-induction of ALA synthase by succinylacetone (SA) in cultured chick embryo liver cells. Conditions of cell cultures were the same as in Fig. 4. Addition of chemicals was made at the time of change of medium after 24 h incubation and cells were then incubated for an additional 24 h. ALA synthase assays were carried out as described previously (8). Data represent the mean±SE for triplicate determinations.From the PDF
FiGURE 6 Possible mechanism of the inhibition of ALA dehydratase by succinylacetone. In the ALA dehydratase reaction, the first molecule of ALA is bound covalently to the enzyme through the formation of a Schiff base between the e-amino group of a lysine residue and the keto group of ALA (step 1). This stabilized carbanion then participates in an aldol condensation with a second ALA molecule (step 2) which, upon the removal of one molecule of water, leads t o oo oon se ( th ALA (shown in bold letters), and thus could compete with ALA binding at step 1, or step 2, or both.
FiGURE 6 Possible mechanism of the inhibition of ALA dehydratase by succinylacetone. In the ALA dehydratase reaction, the first molecule of ALA is bound covalently to the enzyme through the formation of a Schiff base between the e-amino group of a lysine residue and the keto group of ALA (step 1). This stabilized carbanion then participates in an aldol condensation with a second ALA molecule (step 2) which, upon the removal of one molecule of water, leads t o oo oon se ( th ALA (shown in bold letters), and thus could compete with ALA binding at step 1, or step 2, or both.From the PDF

Verification

Claims the paper makes

6 Valid · 1 Not valid · 12 Not checked · 58 Own results and interpretations

44 more claims

Create a free account to see all 77 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 9
  • It may state two separate claims as one. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. [1]1. LaDu, B. N., and L. R. Gjessing. 1978. Tyrosinosis and tyrosinemia. In The Metabolic Basis of Inherited Disease. J. B. Stanbury, J. B. Wyngaarden, and D. S. Frederickson, editors. McGraw-Hill, New York. 4th edition. 256-267.
  2. [38]38. Kappas, A., S. Sassa, and K. E. Anderson. 1982. The porphyrias. In The Metabolic Basis of Inherited Disease. j. B. Śtanbury, J. B. Wyngaarden, D. S. Frederickson, J. S. Goldstein, and M. S. Brown, editors. McGraw-Hill, New York, 5th edition. 1301-1384.

Cited by

See all 148

Metadata

Authors
Sassa, S., & Kappas, A.
Affiliations
Rockefeller University Hospital (US)
Venue
Journal of Clinical Investigation
Published
1983-03-01
Volume
71
Issue
3
Pages
625-634
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2081959583
Cited by
145
References
39
Citations by year
2026: 8 · 2025: 9 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 4 · 2017: 5 · 2016: 8 · 2015: 3 · 2014: 4 · 2013: 2 · 2012: 3
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords
hereditary tyrosinemia, succinylacetone, delta-aminolevulinic acid dehydratase, heme biosynthesis, fumarylacetoacetate hydrolase deficiency, acute intermittent porphyria, competitive inhibition, cytochrome P450, hepatocytes, erythrocytes, pharmacogenetics, urinary metabolites
MeSH terms
Amino Acid Metabolism, Inborn Errors, Porphobilinogen Synthase, Animals, Cattle, Chick Embryo, Erythrocytes, Heme, Heptanoates, Heptanoic Acids, Humans, Liver, Mice, Inbred BALB C, Species Specificity, Tyrosine, Mice, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone. https://app.cochat.ai/papers/10.1172/jci110809
The paper
Sassa, S., & Kappas, A. (1983). Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone. Journal of Clinical Investigation. https://doi.org/10.1172/jci110809

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.